Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy  

作　　者：Qian-jie Tang He-ping Lei Hong Wu Ji-yan Chen Chun-yu Deng Wang-sheng Sheng Yong-heng Fu Xiao-hong Li Yu-bi Lin Ya-ling Han Shi-long Zhong 

机构地区：[1]Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China [2]Medical School of South China University of Technology, Guangzhou, China [3]Department of Pharmacy, Guangdong Women and Children Hospital, Guangzhou, China [4]Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China [5]Cardiovascular Research Institute and Department of Cardiology, Shenyang Northern Hospital, Shenyang, China

出　　处：《Acta Pharmacologica Sinica》2019年第2期208-215,共8页中国药理学报（英文版）

基　　金：National Key R&D program (No 2017YFC0909301 and 2016YFC0905003);National Natural Science Foundation of China (No 81673514, 81373486,81202602,and 81470440);Science and Technology Development Projects of Guangdong Province,China (No 2016B090918114),and Science and Technology Development Projects of Guangzhou,Guangdong,China (201510010236 and 201604020096).

摘　　要：MicroRNAs (miRNAs) are widely expressed in organisms and are implicated in the regulation of most biological functions. The present study investigated the association of plasma miRNAs with the clinical outcomes of dual antiplatelet therapy in coronary artery disease (CAD) patients who underwent percutaneous coronary intervention (PCI). Plasma miRNA levels were screened using high-throughput Illumina sequencing to evaluate the antiplatelet efficacy of clopidogrel and aspirin. Six plasma miRNAs (miR-126, miR-130a, miR-27a, miR-106a, miR-21, and miR-142) were associated with clopidogrel-treated platelet aggregation. These miRNAs were validated in a prospective cohort of 1230 CAD patients using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). High plasma miR-142 levels were associated with a high risk of major adverse cardiovascular events (MACE), with a hazard ratio (95% confidence interval) of 1.83 (1.30–2.59) at a false discovery rate of <5%. Multivariable Cox regression analysis revealed that diabetes mellitus, heart failure, calcium channel blocker application, and a high plasma miR-142 level were independent risk factors of MACE. The levels of the six plasma miRNAs were not significantly associated with bleeding events during the 3-year follow-up. In conclusion, plasma miR-142 is potential marker to predict MACE in CAD patients after PCI.

关 键 词：PLASMA miRNAs miR-142 ANTIPLATELET therapy MACEs CORONARY ARTERY disease 

分 类 号：R[医药卫生]